PENDERGAS,T et al Appl. No. 10/734,582 October 31, 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-6 (Cancelled).

- 7. (Currently Amended) A method of preventing or treating a pathogen infection, wherein said pathogen is a bacterial or viral pathogen, comprising administering to a mammal in need of such prevention or treatment an inhibitor of Abl tyrosine kinase in an amount sufficient to effect said prevention or treatment.
 - 8. (Cancelled).
- 9. (Currently Amended) The method according to claim § 7 wherein said pathogen is a bacterial pathogen.
- 10. (Original) The method according to claim 9 wherein said bacterial pathogen is selected from the group consisting of *Shigella flexneri*, Enteropathogenic *E. coli* and Salmonella.
- 11. (Currently Amended) The method according to claim § 7 wherein said pathogen is a viral pathogen.

PENDERGAST et al Appl. No. 10/734,582 October 31, 2007

- 12. (Original) The method according to claim 10 wherein said viral pathogen is vaccinia.
- 13. (Original) The method according to claim 7 wherein said method is a method of treatment.
- 14. (Original) The method according to claim 7 wherein said method said mammal is a human.
- 15. (Original) The method according to claim 7 wherein said inhibitor inhibits Abl tyrosine kinase indirectly.
- 16. (Previously Presented) The method according to claim 9 wherein the bacterial pathogen is *Shigella*.
- 17. (Previously Presented) The method according to claim 7 wherein said pathogen requires Abl tyrosine kinase to infect mammalian cells.
- 18. (Previously Presented) The method according to claim 17 wherein said pathogen is a bacterial pathogen.
- 19. (Previously Presented) The method according to claim 7 wherein said pathogen catalytically activates Abl tyrosine kinase during infection of mammalian cells.

PENDERGAST et al Appl. No. 10/734,582 October 31, 2007

- 20. (Previously Presented) The method according to claim 7 wherein said inhibitor of Abl tyrosine kinase is STI571.
- 21. (Previously Presented) The method according to claim 20 wherein said pathogen is a bacterial pathogen.
- 22. (Previously Presented) The method according to claim 21 wherein said bacterial pathogen is *Shigella*.
- 23. (New) A method of preventing or treating a pathogen infection, wherein said pathogen is *Shigella flexneri*, comprising administering to a mammal in need of such prevention or treatment an amount of STI571 sufficient to effect said prevention or treatment.
- 24. (New) The method according to claim 23 wherein said method is a method of treatment.
 - 25. (New) The method according to claim 23 wherein said mammal is a human.